Clinical trials: Refractory and/or Relapsed Metastatic Solid Tumors
- Condition Refractory and/or Relapsed Metastatic Solid Tumors
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Solid Tumor, Unresectable or Metastatic Melanoma
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
- Trial name
- NCT03993379
- Testing
- CX-072, Ipilimumab
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- CytomX Therapeutics
Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma
- Trial name
- CD205SHUTTLE (NCT03403725)
- Testing
- MEN1309
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Menarini Group
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Melanoma, Metastatic Melanoma
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion.
- Conditions
- Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
- Trial name
- NCT01425008
- Testing
- MLN2480
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 149 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms, Lymphoma
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
This study is in 2 parts. The main aims of the 1st part of the study are to check if people with advanced solid tumors or cancers in the immune system (lymphomas) have side effects from TAK-981, and to check how much TAK-981 they…
- Conditions
- Neoplasms, Lymphoma, Hematologic Neoplasms
- Trial name
- NCT03648372
- Testing
- TAK-981
- Where
- 8 sites in United States
- Volunteers
- 109 people
- Sponsor
- Takeda
Neoplasm Metastasis
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies.
- Trial name
- NCT02677116
- Testing
- Olaratumab, Doxorubicin, Vincristine
- Where
- 21 sites in United States, Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company